Stocks and Investing
Stocks and Investing
Fri, March 4, 2022
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Bradley Canino Maintained (BPMC) at Strong Buy with Increased Target to $105 on, Mar 4th, 2022
Bradley Canino of Stifel, Maintained "Blueprint Medicines Corporation" (BPMC) at Strong Buy with Increased Target from $100 to $105 on, Mar 4th, 2022.
Bradley has made no other calls on BPMC in the last 4 months.
There are 6 other peers that have a rating on BPMC. Out of the 6 peers that are also analyzing BPMC, 3 agree with Bradley's Rating of Hold. Following are those relevant analyst calls for the last 4 months
- David Lebowitz of "Citigroup" Initiated at Hold on, Tuesday, March 1st, 2022
- Andrew Berens of "SVB Leerink" Downgraded from Buy to Hold and Decreased Target to $82 on, Thursday, February 17th, 2022
- David Lebovitz of "Morgan Stanley" Maintained at Hold with Decreased Target to $92 on, Tuesday, February 1st, 2022
These are the ratings of the 3 analyists that currently disagree with Bradley
- Andrew Fein of "HC Wainwright & Co." Maintained at Strong Buy with Decreased Target to $100 on, Thursday, February 17th, 2022
- Michael Schmitz of "Guggenheim" Maintained at Strong Buy with Increased Target to $122 on, Monday, January 3rd, 2022
- Dane Leone of "Raymond James" Maintained at Strong Buy with Increased Target to $133 on, Wednesday, November 10th, 2021
Contributing Sources